Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | January 02, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date January 02, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2036-01-02 | Direct | 19,547 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 19,547 · Balance 19,547 F1: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 21, 2026 23:10 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 19,547 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000087 · form4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,547 Underlying: Common Stock · 19,547 shares Expires 2036-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:27 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000617 · form4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| January 02, 2025 Filed Jan 9, 2025 00:33 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (right to buy) · Derivative | 31,613 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001415889-25-001164 · form4-01092025_120123.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,613 Underlying: Common Stock · 31,613 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:04 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016092 · form4-06082024_010616.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 22:18 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | PurchaseCommon Stock | 8,000 | $1.23 | $9,840.00 |
DisclosureSEC source: 0001209191-23-045231 · doc4.xml · nonDerivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:49 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-032677 · doc4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 00:41 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-035671 · doc4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 21:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060264 · doc4.xml · derivative · entry 3 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,911 Underlying: Common Stock · 1,000 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 21:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,000 | $88.93 | $88,930.00 |
DisclosureSEC source: 0001209191-21-060264 · doc4.xml · nonDerivative · entry 2 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2021. Read SEC document |
| October 08, 2021 Filed Oct 12, 2021 21:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 1,000 | $17.00 | $17,000.00 |
DisclosureSEC source: 0001209191-21-060264 · doc4.xml · nonDerivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · derivative · entry 7 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,911 Underlying: Common Stock · 6,000 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 48 | $98.90 | $4,747.20 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · nonDerivative · entry 6 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 423 | $97.55 | $41,263.65 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · nonDerivative · entry 5 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.22 to $97.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,429 | $96.51 | $137,912.79 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · nonDerivative · entry 4 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.12 to $97.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,044 | $95.57 | $99,775.08 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · nonDerivative · entry 3 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.07 to $96.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 3,056 | $94.55 | $288,944.80 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · nonDerivative · entry 2 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,944 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.06 to $95.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 21:30 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 6,000 | $17.00 | $102,000.00 |
DisclosureSEC source: 0001209191-21-052285 · doc4.xml · nonDerivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 21:26 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 100 | $55.73 | $5,573.00 |
DisclosureSEC source: 0001209191-21-043707 · doc4.xml · nonDerivative · entry 3 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 21:26 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 250 | $55.03 | $13,757.50 |
DisclosureSEC source: 0001209191-21-043707 · doc4.xml · nonDerivative · entry 2 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 21:26 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 200 | $55.01 | $11,002.00 |
DisclosureSEC source: 0001209191-21-043707 · doc4.xml · nonDerivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:27 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 11,029 | $0.00 Strike: $50.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041714 · doc4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2031-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 16, 2021. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 00:14 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 11,029 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0001209191-20-035421 · doc4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2030-06-07 F1 · derivative.exercise_date: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. Read SEC document |
| May 13, 2019 Filed Mar 12, 2020 20:40 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 550 | $17.00 | $9,350.00 |
DisclosureSEC source: 0001209191-20-018537 · doc4.xml · nonDerivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Read SEC document |
| May 08, 2019 Filed May 9, 2019 21:18 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to buy) · Derivative | 91,911 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028537 · doc4.xml · derivative · entry 1 McLoughlin Margaret · CIK 0001770823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,911 Underlying: Common Stock · 91,911 shares Expires 2029-05-07 F1 · derivative.exercise_date: The option will vest as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.